Hippo Holdings Valuation
Is HIPO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HIPO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HIPO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HIPO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HIPO?
Key metric: As HIPO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is HIPO's PS Ratio? | |
|---|---|
| PS Ratio | 2.1x |
| Sales | US$334.70m |
| Market Cap | US$708.87m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | -4.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does HIPO's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
ABL Abacus Life | 6.5x | 37.8% | US$629.3m |
SLQT SelectQuote | 0.3x | 10.5% | US$432.2m |
CRD.B Crawford | 0.4x | 6.1% | US$555.6m |
WDH Waterdrop | 1.1x | 9.9% | US$420.6m |
HIPO Hippo Holdings | 2.1x | 17.6% | US$708.9m |
Price-To-Sales vs Peers: HIPO is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (2.1x).
Price to Sales Ratio vs Industry
How does HIPO's PS Ratio compare vs other companies in the US Insurance Industry?
Price-To-Sales vs Industry: HIPO is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Insurance industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is HIPO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.1x |
| Fair PS Ratio | 1x |
Price-To-Sales vs Fair Ratio: HIPO is expensive based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$28.76 | US$27.67 -3.8% | 16.3% | US$34.00 | US$24.00 | n/a | 3 |
| Nov ’25 | US$21.37 | US$24.67 +15.4% | 11.6% | US$28.00 | US$21.00 | n/a | 3 |
| Oct ’25 | US$16.47 | US$25.00 +51.8% | 13.1% | US$29.00 | US$21.00 | n/a | 3 |
| Sep ’25 | US$19.85 | US$25.00 +25.9% | 13.1% | US$29.00 | US$21.00 | n/a | 3 |
| Aug ’25 | US$16.39 | US$23.00 +40.3% | 9.4% | US$25.00 | US$20.00 | n/a | 3 |
| Jul ’25 | US$16.03 | US$24.67 +53.9% | 8.3% | US$27.00 | US$22.00 | n/a | 3 |
| Jun ’25 | US$17.64 | US$24.67 +39.8% | 8.3% | US$27.00 | US$22.00 | n/a | 3 |
| May ’25 | US$21.97 | US$24.67 +12.3% | 11.6% | US$28.00 | US$21.00 | n/a | 3 |
| Apr ’25 | US$19.27 | US$23.00 +19.4% | 7.1% | US$25.00 | US$21.00 | n/a | 3 |
| Mar ’25 | US$14.68 | US$19.67 +34.0% | 19.6% | US$25.00 | US$16.00 | n/a | 3 |
| Feb ’25 | US$9.27 | US$17.50 +88.8% | 28.7% | US$25.00 | US$11.00 | n/a | 4 |
| Jan ’25 | US$9.12 | US$18.00 +97.4% | 28.6% | US$25.00 | US$11.00 | n/a | 4 |
| Dec ’24 | US$8.92 | US$18.00 +101.8% | 28.6% | US$25.00 | US$11.00 | n/a | 4 |
| Nov ’24 | US$7.21 | US$18.50 +156.6% | 29.2% | US$25.00 | US$10.00 | US$21.37 | 4 |
| Oct ’24 | US$7.97 | US$27.50 +245.0% | 47.3% | US$50.00 | US$19.00 | US$16.47 | 4 |
| Sep ’24 | US$10.48 | US$32.50 +210.1% | 40.0% | US$50.00 | US$19.00 | US$19.85 | 4 |
| Aug ’24 | US$17.36 | US$40.50 +133.3% | 48.8% | US$70.00 | US$22.00 | US$16.39 | 4 |
| Jul ’24 | US$16.53 | US$41.00 +148.0% | 47.1% | US$70.00 | US$22.00 | US$16.03 | 4 |
| Jun ’24 | US$15.56 | US$41.00 +163.5% | 47.1% | US$70.00 | US$22.00 | US$17.64 | 4 |
| May ’24 | US$18.62 | US$41.00 +120.2% | 47.1% | US$70.00 | US$22.00 | US$21.97 | 4 |
| Apr ’24 | US$16.23 | US$41.00 +152.6% | 47.1% | US$70.00 | US$22.00 | US$19.27 | 4 |
| Mar ’24 | US$16.59 | US$41.00 +147.1% | 47.1% | US$70.00 | US$23.00 | US$14.68 | 4 |
| Feb ’24 | US$17.67 | US$41.00 +132.0% | 47.1% | US$70.00 | US$23.00 | US$9.27 | 4 |
| Jan ’24 | US$13.60 | US$47.50 +249.3% | 45.4% | US$70.00 | US$24.00 | US$9.12 | 4 |
| Dec ’23 | US$14.32 | US$41.50 +189.8% | 54.7% | US$70.00 | US$17.50 | US$8.92 | 5 |
| Nov ’23 | US$17.99 | US$58.88 +227.3% | 36.7% | US$86.00 | US$28.00 | US$7.21 | 4 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Sagicor Financial
CA$867.3m
Provides insurance products and related financial services in Jamaica, Barbados, Trinidad, Tobago, other Caribbean region, and the United States.
SGCF.F
CA$4.46
7D
0%
1Y
-0.5%
Fidelis Insurance Holdings
US$2.2b
A specialty insurer, provides insurance and reinsurance solutions in Bermuda, the Republic of Ireland, and the United Kingdom.
FIHL
US$19.90
7D
-0.2%
1Y
62.1%
Markel Group
US$21.5b
A diverse holding company, engages in marketing and underwriting specialty insurance products in the United States, Bermuda, the United Kingdom, and Germany.
MKL
US$1,694.12
7D
2.3%
1Y
18.5%